Speed Is Necessary but Not Sufficient: Aligning Direct-From-Blood Diagnostics with Stewardship to Reduce Empiric Broad-Spectrum Antibiotic Use

To the Editor—Gaston et al [1] report a pragmatic randomized trial evaluating direct-from-blood bacterial testing in addition to conventional blood cultures versus blood cultures alone among 500 emergency department (ED) adults receiving empiric intravenous vancomycin. The intervention markedly accelerated microbiologic diagnosis, reducing the median time to a definitive result from 5.5 days to 0.4 days [1]. Despite this substantial diagnostic gain, no corresponding reduction in empiric antibiotic exposure was observed: the time to the last vancomycin dose (median, 12.5 vs 19.0 hours; hazard ratio [HR], 1.08) and to the last antipseudomonal β-lactam dose (median, 1.6 vs 1.7 days; HR, 1.04) did not differ significantly between groups [1]. Collectively, these findings highlight a persistent challenge in sepsis diagnostics—accelerated pathogen identification alone does not necessarily translate into earlier antimicrobial de-escalation [2]. Several factors likely attenuated the measurable impact of faster testing. First, a floor effect is probable. Median vancomycin exposure in both groups was less than 24 hours, leaving limited opportunity for further reduction in an unselected ED population [1]. Second, actionable confidence is as critical as turnaround time. Only 83.3% of intervention patients obtained a direct-from-blood result, and false-negative Staphylococcus aureus findings were observed, potentially discouraging clinicians from stopping empiric coverage [1]. Prior diagnostic accuracy and ED-based evaluations of the same platform demonstrate variable performance and highlight the importance of local validation and clinician trust [3, 4]. Third, restricted pathogen coverage may constrain de-escalation. An assay limited to a small number of on-panel organisms may not sufficiently reassure clinicians managing patients at risk for off-panel bacteremia, particularly in settings where guidelines emphasize immediate broad empiric therapy for severe infection [5].